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Sumoylation of AMPKβ2 subunit enhances 
AMP-activated protein kinase activity
Teresa Rubio, Santiago Vernia, and Pascual Sanz
Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, and Centro de Investigación en 
Red de Enfermedades Raras, 46010-Valencia, Spain
ABSTRACT AMP-activated protein kinase (AMPK) is a sensor of cellular energy status. It is a 
heterotrimer composed of a catalytic α and two regulatory subunits (β and γ). AMPK activity 
is regulated allosterically by AMP and by the phosphorylation of residue Thr-172 within the 
catalytic domain of the AMPKα subunit by upstream kinases. We present evidence that the 
AMPKβ2 subunit may be posttranslationally modified by sumoylation. This process is carried 
out by the E3-small ubiquitin-like modifier (SUMO) ligase protein inhibitor of activated STAT 
PIASy, which modifies the AMPKβ2 subunit by the attachment of SUMO2 but not SUMO1 
moieties. Of interest, AMPKβ1 is not a substrate for this modification. We also demonstrate 
that sumoylation of AMPKβ2 enhances the activity of the trimeric α2β2γ1 AMPK complex. In 
addition, our results indicate that sumoylation is antagonist and competes with the ubiquit-
ination of the AMPKβ2 subunit. This adds a new layer of complexity to the regulation of the 
activity of the AMPK complex, since conditions that promote ubiquitination result in inactiva-
tion, whereas those that promote sumoylation result in the activation of the AMPK complex.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a serine/threonine protein 
kinase that acts as a sensor of cellular energy status. It is a het-
erotrimer composed of three different subunits: α, β, and γ. AMPKα 
is the catalytic subunit of the AMPK complex; it contains a highly 
conserved kinase domain located at the N-terminus of the protein, 
followed by an autoinhibitory domain (Pang et al., 2007) and a C-
terminal domain required for interaction with the AMPKβ subunit 
(Xiao et al., 2007). Two isoforms of the catalytic subunit have been 
described, α1 and α2. The AMPKγ subunit contains four repeats in 
tandem of a structural module called a CBS motif, described initially 
in the enzyme cystathionine β-synthase (Bateman, 1997), involved in 
AMP binding (Scott et al., 2004; Xiao et al., 2007). Three isoforms 
have been described for this subunit: γ1, γ2, and γ3. Finally, the 
AMPKβ subunit functions as a scaffold to assemble α and γ subunits 
and also may affect subcellular localization and substrate specificity 
of the complex. Two isoforms of the β-subunit (β1 and β2) have 
been described; they differ in their N-terminal regions, but they in-
teract with the same efficiency with AMPKα and AMPKγ subunits 
(Gimeno-Alcaniz and Sanz, 2003). AMPK activity is regulated by al-
losteric activation by AMP and the phosphorylation of Thr-172 resi-
due within the catalytic domain of α subunit by upstream kinases 
(for review see Sanz, 2008; Carling et al., 2012). In addition to al-
losteric regulation, AMP prevents the action of phosphatases that 
promote dephosphorylation of the Thr-172 residue by making 
AMPK a poorer substrate for these phosphatases (Davies et al., 
1995; Sanders et al., 2007).
Although phosphorylation of AMPK is key to regulating AMPK 
activity, recently other posttranslational modifications have been 
described that affect the function of the AMPK complex. The AMPKα 
catalytic subunit may be acetylated by p300 acetyltransferase. 
Acetylation of AMPKα regulates the interaction between AMPK and 
the upstream kinase LKB1, providing a direct mechanism for regu-
lating phosphorylation of AMPK by LKB1 (Lin et al., 2012).
In addition, recent studies have identified different mechanisms 
by which the ubiquitin proteasome system regulates AMPK activity. 
Ubiquitination of AMPKα1 has been reported. Of interest, the 
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hances AMPK total activity and protects the AMPKβ2 subunit from 
being modified by ubiquitination.
RESULTS
AMPK interacts physically with PIASy
In a previous yeast two-hybrid screening using AMPKβ2 as bait, we 
identified PIASy as a putative interaction partner. To study the possi-
ble functional relationship between AMPK and PIASy, we quantified 
by yeast two-hybrid assay the interaction between different AMPK 
subunits and PIASy. In the assays, we used the catalytic AMPKα2 sub-
unit, the scaffolding AMPKβ1 and β2 subunits, and the regulatory 
AMPKγ1. As shown in Figure 1A, we detected a robust two-hybrid 
interaction between PIASy and α2 catalytic and β1 and β2 regulatory 
polyubiquitin chains present were made by atypical (K29 and K33) 
ubiquitin linkages, but the possible effect of this modification on 
AMPK activity was not studied (Al-Hakim et al., 2008). Other work 
indicated that AMPKβ subunits were ubiquitinated by a cell death–
inducing, DFFA-like effector A (CIDEA)–dependent E3-ubiquitin li-
gase, which targeted the AMPKβ subunits for proteasomal degrada-
tion (Qi et al., 2008). Our group also demonstrated the ubiquitination 
of the AMPKβ subunits carried out by a complex formed by the 
glucan phosphatase laforin and the E3-ubiquitin ligase malin. How-
ever, in this case the modification did not target the AMPKβ sub-
units for proteasomal degradation, since the polyubiquitin chains 
were mainly made by K63-ubiquitin linkages, with this modification 
related to nondegradative functions (Moreno et al., 2010).
In this article, we present evidence that sumoylation is a novel 
posttranslational modification of AMPK complex. Sumoylation con-
sists in a reversible covalent attachment of a member of the small 
ubiquitin-like modifier (SUMO) family of ubiquitin-related peptides 
to lysine residues in target proteins in a process similar to ubiquitina-
tion (Gareau and Lima, 2010; Wilkinson and Henley, 2010). Whereas 
yeast possesses a single SUMO protein, Smt3p, there are three hu-
man SUMO paralogues: SUMO1, SUMO2, and SUMO3. SUMO2 
and SUMO3 are 96% identical to each other and are functionally 
redundant. However SUMO1 is only 45% identical to SUMO2/3 and 
has different properties when attached to a particular substrate 
(Gareau and Lima, 2010; Wilkinson and Henley, 2010). Of interest, 
SUMO2 and SUMO3 can form SUMO chains, whereas SUMO1 is 
only able to form monosumoylated derivatives, or it can be attached 
to the end of a SUMO2/3 chain (Tatham et al., 2005; Hay, 2007; 
Gareau and Lima, 2010). The sumoylation reaction requires the 
SUMO-activating E1 enzyme Aos1/Uba2 and the SUMO-conjugat-
ing E2 enzyme Ubc9 (Gareau and Lima, 2010; Wilkinson and Henley, 
2010). Ubc9 recognizes a minimal sumoylation motif in many known 
targets (ΨKXD/E, with Ψ any hydrophobic residue and X any resi-
due). Although target proteins interact at least transiently with Ubc9, 
their efficient conjugation often requires E3-SUMO ligases (Muller 
et al., 2004). There are three types of E3-SUMO ligase (Muller et al., 
2004): RanBP2/Nup358 (Pichler et al., 2004), the Polycomb member 
Pc2 (Kagey et al., 2003), and the protein inhibitor of activated STAT 
(PIAS) family, which were originally identified as transcriptional co-
regulators of the JAK-STAT pathway (Rytinki et al., 2009). Mammals 
have at least five members in the PIAS family: PIAS1, PIAS3, PIASxα, 
PIASxβ, and PIASy (Rytinki et al., 2009).
In contrast to ubiquitination, poly-SUMO modification does not 
usually trigger protein degradation. Instead, sumoylation may affect 
subcellular localization, protein–protein interaction, transcriptional 
activation, and protein stability of the corresponding target (Gareau 
and Lima, 2010; Wilkinson and Henley, 2010). Owing to the great 
similarities between ubiquitination and sumoylation systems, a 
growing number of proteins are being described as substrates for 
both ubiquitination and sumoylation, sometimes in the same lysine 
residues. These two types of posttranslational modification are 
sometimes viewed as antagonists and control the properties of the 
targeted protein in a competitive manner (Ulrich, 2005; Wilson 
and Heaton, 2008; Bergink and Jentsch, 2009). For example, 
sumoylation on the Lys-21 residue of IκBα protein blocks its ubiquit-
ination and degradation by direct competition for the modification 
site (Desterro et al., 1998), and sumoylation of aryl hydrocarbon 
receptor modulates its activity and stability by inhibiting its ubiquit-
ination (Xing et al., 2012).
In this work we show that AMPKβ2 but not AMPKβ1 subunit can 
be modified by sumoylation, with this process being carried out by 
the E3-SUMO ligase PIASy. This posttranslational modification en-
FIGURE 1: AMPK interacts physically with PIASy. (A) Yeast two-hybrid 
analysis. Yeast CTY10.5d cells transformed with plasmid pBTM116 
(empty, ∅), pBTM-AMPKα2, pBTM-AMPKβ2, or pBTM-AMPKγ1 were 
cotransformed with plasmid pACT2-PIASy. Protein interaction was 
estimated by using the yeast two-hybrid system by measuring the 
β-galactosidase activity. Values correspond to means from four to six 
different transformants (bars, ±SD). (B) The three subunits of the 
AMPK complex coimmunoprecipitate with PIASy. Protein extracts 
(1.2 mg) were prepared from HEK293 cells cotransfected with 
plasmids pCMV-myc-AMPKα2/β2/γ1 and pFLAG-PIASy or pFLAG 
(empty, ∅). One microliter of anti-FLAG was used to 
immunoprecipitate the extracts (IP). Pelleted proteins and proteins in 
the input crude extracts (CE; 40 μg) were analyzed by SDS–PAGE and 
immunodetected (WB) with anti-AMPKα, anti-AMPKβ, anti-AMPKγ, 
and anti-PIASy antibodies. Molecular-size markers are indicated. 
(C) Human U2OS cells were treated with 6 μM MG132 for 8 h to 
prevent the degradation of endogenous PIASy. Then protein extracts 
(1.2 mg) were immunoprecipitated with 1 μl of anti-PIASy (IP PIASy) or 
preimmune serum (IP preim). Pelleted proteins and proteins in the 
input crude extracts (CE; 40 μg) were analyzed by SDS–PAGE and 
immunodetected as in B.
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and a combination of AMPKα2, AMPKβ2, 
and AMPKγ1 in order to produce a heterotri-
meric AMPK complex. As shown in Figure 
1B, when FLAG-PIASy was immunoprecipi-
tated with anti-FLAG antibodies, AMPKα2, 
AMPKβ2, and AMPKγ1 were also recovered 
in the immunoprecipitates, indicating that 
the interaction of PIASy with AMPK subunits 
was able to immunoprecipitate the whole 
AMPK complex. In the same way, if myc-
AMPKβ2 was immunoprecipitated using anti-
bodies against the protein tag (myc), in addi-
tion to the other two AMPK subunits (AMPKα2 
and AMPKγ1, which confirmed the formation 
of heterotrimeric complexes upon overex-
pression of the three subunits), we also recov-
ered FLAG-PIASy in the immunoprecipitates 
(Supplemental Figure S1). To confirm the 
interaction at endogenous levels, we used 
human U2OS cells, since they express the 
highest levels of endogenous AMPKβ2 sub-
unit among all cell types tested (HEK293, 
CHO, COS7, SH-SY5Y, HeLa; data not 
shown). These cells were treated with MG132 
(a proteasomal inhibitor) to prevent the deg-
radation of endogenous PIASy, and then cell 
extracts were immunoprecipitated using anti-
PIASy antibodies. As shown in Figure 1C, en-
dogenous AMPK subunits (α, β1, β2, and γ1) 
were recovered in the immunoprecipitate, 
but this reaction did not occur when preim-
mune serum was used in the assay. These 
results confirmed the physical interaction be-
tween the AMPK complex and PIASy.
PIASy, an E3-SUMO ligase, promotes 
SUMO2-specific sumoylation of 
AMPKβ2 subunit
Because PIASy is a member of the PIAS fam-
ily of E3-SUMO ligases (Rytinki et al., 2009), 
we decided to examine whether PIASy was 
able to promote the sumoylation of the 
AMPK subunits. The sumoylation event can 
be carried out by the addition of different 
SUMO isoforms, with SUMO1, SUMO2, and 
SUMO3 the most abundant moieties. Be-
cause SUMO2 and SUMO3 are highly simi-
lar (Rytinki et al., 2009), we set up an assay 
for the analysis of sumoylated proteins 
based on the expression of a hexahistidine 
(6xHis)-tagged version of SUMO1 or 
SUMO2. Cell extracts were prepared in the 
presence of the chaotropic agent guanidin-
ium hydrochloride to inhibit desumoylating 
enzymes, and sumoylated proteins were 
purified by metal-affinity chromatography. 
This purified fraction was analyzed by SDS–
PAGE and Western blotting using specific 
antibodies against the protein of interest. 
We coexpressed in HEK293 cells the three AMPK complex subunits 
(α2, β2, and γ1) and 6xHis-SUMO1 or 6xHis-SUMO2 in the presence 
or absence of FLAG-PIASy. As shown in Figure 2A, PIASy was not 
subunits of the AMPK complex but not with the regulatory AMPKγ1 
subunit. To confirm the physical interaction between AMPK subunits 
and PIASy, we coexpressed in mammalian HEK293 cells FLAG-PIASy 
FIGURE 2: PIASy promotes the sumoylation of AMPKβ2 subunit. (A) PIASy promotes the 
SUMO2-dependent sumoylation of AMPKβ2 but does not affect AMPKα2. HEK293 cells were 
cotransfected with plasmids pCMV-6xHis-SUMO1 or pCMV-6xHis-SUMO2, pCMV-myc-
AMPKα2/β2/γ1, and pFLAG-PIASy or pFLAG (empty). Cell extracts were obtained and 
sumoylated proteins purified by metal-affinity chromatography as described in Materials and 
Methods. Clarified extract (CE; 40 μg) and the material bound to the metal-affinity 
chromatography column (Bound) was analyzed by SDS–PAGE and Western blotting using 
anti-AMPKα (left) and anti-AMPKβ (right) antibodies. (B) PIASy does not promote the 
sumoylation of the AMPKβ1 subunit. HEK293 cells were transfected with plasmids pCMV-6xHis-
SUMO1 or pCMV-6xHis-SUMO2, pCMV-myc-AMPKα2/γ1, pCMV-myc-AMPKβ1 instead of 
AMPKβ2, and pFLAG-PIASy or pFLAG (empty). Cell extracts were analyzed as described using 
anti-AMPKβ antibody. (C) Sumoylation of AMPKβ2 is dependent on PIASy activity. HEK293 cells 
were cotransfected with plasmids pCMV-6xHis-SUMO2, pCMV-myc-AMPKα2/β2/γ1, and 
pFLAG-PIASy or pFLAG-PIASy-CI (expressing a form of PIASy with reduced catalytic activity) or 
pFLAG (empty). Cell extracts were analyzed as described using anti-AMPKβ antibody. 
(D) Human U2OS cells were transfected with plasmids pCMV-6xHis-SUMO2 and pFLAG-PIASy 
or pFLAG (empty) and treated with 6 μM MG132 for 8 h. Cell extracts were analyzed as 
described using anti-AMPKβ antibody. (E) Sumoylation of free AMPKβ2 subunit is independent 
of PIASy expression. HEK293 cells were cotransfected with plasmids pCMV-6xHis-SUMO2, 
pCMV-myc-AMPKβ2, and pFLAG-PIASy or pFLAG (empty). Cell extracts were analyzed as 
described using anti-AMPKβ antibody. Molecular-size markers are indicated on the side; the 
presence of poly/multisumoylated proteins is indicated.
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conformational change in the protein that makes other lysine 
residues more accessible for sumoylation.
To identify the lysine residues involved in the sumoylation pro-
cess, and due to the fact that AMPKβ2 contains 20 lysine residues in 
its protein sequence, we decided to map the regions involved in the 
PIASy-dependent sumoylation by constructing two truncated forms 
of AMPKβ2, one containing an N-terminal fragment (residues 1–185; 
molecular weight, 20 kDa) comprising the glycogen-binding do-
main (GBD) and the other including the C-terminal region (residues 
186–272; 10 kDa) containing the so-called “association with Snf1 
complex domain” (ASC) involved in binding to both AMPKα and 
AMPKγ subunits. As shown in Figure 4A, when we coexpressed 
these forms with the rest of the AMPK subunits (AMPKα and AMPKγ), 
we detected sumoylated products in the ASC fragment in the pres-
ence of FLAG-PIASy. The molecular weight of these modified prod-
ucts corresponded to the incorporation of one to five SUMO2 moi-
eties (11 kDa each). However, in the case of the GBD fragment, 
although the sumoylation reaction also occurred, it was indepen-
dent of PIASy coexpression, probably because, since this fragment 
has lost its capacity to interact with AMPKα2 and AMPKγ1 to make 
a trimeric complex (as reported in Iseli et al., 2005), its sumoylation 
becomes PIASy independent, as indicated earlier for the sumoyla-
tion of free AMPKβ2 subunit (Figure 2E). To find which lysine residue 
of the ASC domain was sumoylated, and because we indicated ear-
lier that only AMPKβ2 but not AMPKβ1 follows a PIASy-dependent 
sumoylation, we compared the protein sequence of AMPKβ1 and 
AMPKβ2 in order to find lysine residues present in AMPKβ2 but not 
in AMPKβ1 (Figure 4B). The ASC domain contained six lysine resi-
dues present in both AMPKβ1 and AMPKβ2, but K203 was present 
only in AMPKβ2 (instead, an arginine residue is present in AMPKβ1; 
Figure 4B). We mutated this residue to arginine (K203R), but the 
able to promote the sumoylation of AMPKα2 in any condition (the 
observed band corresponds to nonspecific binding of AMPKα2 to 
the column). However, we observed an efficient PIASy-dependent 
sumoylation of AMPKβ2 subunit, but only when 6xHis-SUMO2 was 
present (lack of sumoylation using SUMO1 was not due to a defi-
cient SUMO1 moiety, since the same construct allowed an efficient 
sumoylation of p53; data not shown). Because we observed a two-
hybrid interaction of PIASy with both AMPKβ1 and β2 subunits 
(Figure 1A), we extended our analysis of PIASy-dependent sumoy-
lation to the AMPKβ1 subunit. Surprisingly, we found that PIASy 
was not able to promote the sumoylation of this isoform with ei-
ther SUMO1 or SUMO2 (Figure 2B). To discard the possibility that 
sumoylation of the AMPKβ2 subunit could be nonspecific and 
independent of PIASy activity, we repeated the experiment by 
expressing a form of PIASy with decreased activity (PIASy-CI, 
containing a double C342A/C347A mutation in the catalytic site 
(Mabb et al., 2006), which diminishes its activity). As shown in 
Figure 2C, PIASy-CI was not able to carry out an efficient sumoyla-
tion of AMPKβ2 subunit compared with wild-type PIASy. Finally, 
we analyzed the PIASy-dependent sumoylation of the endogenous 
AMPK complex. Human U2OS cells transfected with plasmids ex-
pressing 6xHis-SUMO2 in the presence or absence of FLAG-PIASy 
were treated with 6 μM MG132 for 8 h (a treatment that improves 
the sumoylation reaction since, as indicated earlier, by inhibiting 
proteasome activity, it prevents PIASy degradation). Then sumoy-
lated proteins were purified as described. As shown in Figure 2D, 
PIASy was also able to promote the sumoylation of endogenous 
AMPKβ.
Free AMPK subunits are less stable than when they form part of 
a heterotrimeric complex (Crute et al., 1998). Because we reported 
that ubiquitination, a posttranslational modification similar to su-
moylation, affects AMPK subunits in a different way depending on 
whether they form part of a heterotrimeric complex or are expressed 
as free subunits (Moreno et al., 2010), we analyzed the sumoylation 
of AMPKβ2 subunit in cells overexpressing only this subunit. As 
shown in Figure 2E, sumoylation of free AMPKβ2 subunit occurred, 
but it was independent of PIASy. This result confirms previous ob-
servations that individual subunits of the AMPK complex may follow 
alternative routes of posttranslational modifications that render 
them more unstable.
Taken together, these results indicate that PIASy can promote 
the selective sumoylation of AMPKβ2 subunit in the AMPK complex 
and that this modification is specific for SUMO2 isoform.
Sumoylation frequently occurs on a lysine residue within a 
ΨKXD/E consensus sequence, with Ψ any hydrophobic residue 
and X any residue (Gareau and Lima, 2010; Wilkinson and Hen-
ley, 2010). To identify the lysine residues sumoylated in AMPKβ2 
by PIASy, we initially followed a bioinformatics approach using 
the SUMOsp-SUMOylation Sites Prediction program (Ren et al., 
2009). This program identified two putative type II nonconsensus 
sites for sumoylation: DSVK71PTQ and DALK167LDS. We mutated 
lysine residues 71 and 167 to arginine (AMPKβ2 K71R, AMPKβ2 
K167R, and double mutant AMPKβ2 K71R/K167R) and coex-
pressed these mutants with the rest of AMPK subunits (AMPKα2, 
AMPKγ1) to make a heterotrimeric complex and with 6xHis-
SUMO2 and FLAG-PIASy. As shown in Figure 3, when the 
AMPKβ2 mutated forms were used in the assay, a clear PIASy-
dependent sumoylation of these modified subunits was detected. 
These results suggest that these residues are not major sites of 
sumoylation. The results presented in Figure 3 also suggest that 
sumoylation of the mutated forms is more efficient than for wild 
type. Perhaps the introduction of these mutations produces a 
FIGURE 3: Mutation in consensus sumoylation sites of AMPKβ2 does 
not decrease its modification. HEK293 cells were cotransfected with 
plasmids pCMV-6xHis-SUMO2, pFLAG-PIASy or pFLAG (empty), 
pCMV-myc-AMPKα2/γ1 and pCMV-myc-AMPKβ2 or pCMV-myc-
AMPKβ2 K71R, or pCMV-myc-AMPK K167R or the double mutant 
pCMV-myc-AMPKβ2 K71R,K167R. Cell extracts were analyzed as 
described in Figure 2 by using anti-AMPKβ antibody. Molecular-size 
markers are indicated on the left. Presence of poly/multisumoylated 
proteins is indicated.
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due by an arginine modified the conformation of the protein, mak-
ing it more accessible to sumoylation.
Effect of PIASy-dependent sumoylation of AMPKβ2 
on the stability and function of the AMPK complex
We next studied the effect of the PIASy-dependent sumoylation of 
AMPKβ2 on the stability and function of the AMPK complex. We 
first analyzed whether the sumoylation event affected the half-life of 
the protein. With this aim, we expressed in HEK293 cells the het-
erotrimeric AMPK complex (AMPKα2/β2/γ1) and 6xHis-SUMO2 in 
the presence or absence of FLAG-PIASy. Then we treated cells with 
cycloheximide to inhibit new protein synthesis and measured deg-
radation rates of the protein by Western blot. As shown in Figure 6, 
PIASy-dependent sumoylation of AMPKβ2 did not affect the half-life 
of this protein. Therefore the sumoylation of AMPKβ2 does not af-
fect the stability of this protein.
We also studied whether sumoylation affected the subcellular 
distribution of AMPKβ2. Consistent with previous results (Moreno 
et al., 2010), the expression in HEK293 cells of the heterotrimeric 
AMPK complex (α2/β2/γ1) resulted in a spotted distribution of the 
AMPKβ2 protein throughout the cell (Figure 7A, top). However, the 
coexpression of PIASy and SUMO2 produced a distinct pattern of 
cytoplasmic distribution: AMPKβ2 subunit was detected in intracel-
lular deposits dispersed through the cells (Figure 7A, bottom). On 
the contrary, PIASy showed a prominent nuclear localization (Figure 
7A, bottom). We repeated the same experiments with endogenous 
levels of AMPK complex but were unable to detect any alteration of 
AMPK localization upon PIASy overexpression, probably due to the 
low levels of endogenous AMPKβ2 (data not shown). Given that the 
AMPK complex travels continuously between the nucleus and 
the cytosol (Kazgan et al., 2010; Supplemental Figure S2A), it is 
probable that AMPKβ2 is modified by PIASy when it is in the nuclear 
truncated form containing this mutation became very unstable, pre-
cluding further analysis. Thus we analyzed the sumoylation of a full-
length AMPKβ2 K203R mutant and observed that it was still able to 
support a PIASy-dependent sumoylation (Figure 5). This result indi-
cated that AMPKβ2, in addition to a putative sumoylation site at the 
C-terminus, should contain multiple sumoylation sites at the N-
terminus. In fact, when we compared the protein sequences of 
AMPKβ1 and AMPKβ2, we observed four lysine residues in the GBD 
domain of AMPKβ2 that were absent in the corresponding domain 
of AMPKβ1 (K31-D, K57-E, K107-R, and K167-M; Figure 4B).
In addition to the aforementioned mutant, by serendipity we 
also constructed the AMPKβ2 K262R mutant, affecting one lysine 
residue at the C-terminal part of the protein (Figure 4B). When we 
analyzed the PIASy-dependent sumoylation of this mutant we ob-
served that the efficiency of the modification was higher than for 
wild type (Figure 5) and the highest among the mutants tested in 
this work. For this reason we considered it as a PIASy-dependent 
“hypersumoylable” mutant. Perhaps the change of this lysine resi-
FIGURE 4: PIASy is able to promote the sumoylation of a C-terminal 
fragment of AMPKβ2. (A) HEK293 cells were cotransfected with 
pCMV-6xHis-SUMO2, pCMV-myc-AMPKα2/γ1, and pCMV-myc-
AMPKβ2 (1–185), expressing the N-terminal domain, or pCMV-myc-
AMPKβ2 (186–272), expressing the C-terminal domain, and pFLAG-
PIASy or pFLAG (empty). Cell extracts were analyzed as described in 
Figure 2 by using anti-AMPKβ or anti-myc antibodies. The calculated 
size of SUMO-modified forms is indicated. Asterisk indicates possible 
degradation products. ASC, association with Snf1 complex domain; 
GBD, glycogen-binding domain. The presence of poly/
multisumoylated proteins is indicated. (B) Alignment of human 
AMPKβ1 vs. AMPKβ2 protein sequences. The lysine residues in 
AMPKβ2 are indicated in a black box. Lysine residues mutated to 
arginine analyzed in this work are underlined.
FIGURE 5: PIASy-dependent sumoylation of AMPKβ2 K203R and 
K262R mutants. HEK293 cells were transfected with plasmids 
pCMV-6xHis-SUMO2, pFLAG-PIASy (+) or pFLAG (–), pCMV-myc-
AMPKα2/γ1, and pCMV-myc-AMPKβ2 or pCMV-myc-AMPKβ2 K203R 
or pCMV-myc-AMPKβ2 K262R mutants. Cell extracts were analyzed 
as described in Figure 2 by using anti-AMPKβ antibodies. The 
presence of poly/multisumoylated proteins is indicated.
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mutant described earlier (Figure 5) in order to magnify possible dif-
ferences in activity. First we checked that the expression of AMPKβ2 
K262R in combination with AMPKα2 and AMPKγ1 resulted in an 
AMPK complex that was activated by phenformin similar to wild 
type (Figure 8A, left and middle). Treatment of the cells with this 
drug resulted in higher levels of both phospho–Thr-172 AMPKα2 
and endogenous phospho–Ser-79 ACC after 30–60 min in both 
wild-type and AMPKβ2 K262R–containing AMPK complexes. How-
ever, if in the latter cells we coexpressed in addition PIASy and 
SUMO2, we observed a constitutive activation of the AMPK com-
plex: higher levels of both phospho–Thr-172 AMPKα2 and endog-
enous phospho–Ser-79 ACC were detected in untreated cells, and 
treatment with phenformin did not increase significantly the levels 
of these phosphorylated proteins (Figure 8A, right). These results 
suggested that the PIASy-dependent sumoylation of AMPKβ2 re-
sults in constitutive activation of the AMPK complex. To confirm 
these results, we measured the kinase activity of the corresponding 
AMPK complexes by in vitro kinase assays. We immunoprecipitated 
the AMPK complexes in cells expressing the trimeric complex 
(AMPKα2, AMPKβ2 [wild type or K262R], AMPKγ1) in the presence 
or absence of PIASy and SUMO2. These immunoprecipitates were 
used in in vitro kinase assays to measure the intrinsic kinase activity 
of the corresponding complex. In agreement with the results pre-
sented earlier, we detected higher kinase activity (more than two-
fold) in AMPK complexes containing AMPKβ2 K262R that had been 
sumoylated (Figure 8B). Taken together, these results indicate that 
sumoylation of AMPK complex enhances its catalytic activity.
Sumoylation and ubiquitination of AMPKβ2 are antagonistic 
processes
AMPKβ2 can be posttranslationally modified by ubiquitination (Qi 
et al., 2008; Moreno et al., 2010). Depending on the E3-ubiquitin 
ligase involved in the process, ubiquitination results in an enhanced 
degradation of AMPKβ2 (Qi et al., 2008) or in an increase in the 
steady-state levels of the protein due to the appearance of intracel-
lular aggregates (Moreno et al., 2010). Because both sumoylation 
and ubiquitination occurs on Lys residues, a possible competition 
between these two processes could occur, affecting the fate of the 
protein (Anderson et al., 2012; Xing et al., 2012). To check whether 
ubiquitination of AMPKβ2 could affect its PIASy-dependent sumoy-
lation, we coexpressed in HEK293 cells the three AMPK subunits 
(α2/β2/γ1), 6xHis-SUMO2, and FLAG-PIASy in the presence or ab-
sence of hemagglutinin (HA)-ubiquitin. As shown in Figure 9A, the 
presence of HA-ubiquitin greatly reduced the levels of sumoylated 
AMPKβ2. This could indicate competition of sumoylation and ubiq-
uitination for posttranslational modification of AMPKβ2. To confirm 
this result, we analyzed the ubiquitination of AMPKβ2 subunit in the 
presence or absence of PIASy and SUMO2 in cells treated with 
MG132 (a proteasomal inhibitor) to enhance the accumulation of 
ubiquitinated proteins. As shown in Figure 9B, the expression of 
PIASy and SUMO2 decreased the ubiquitination of AMPKβ2 subunit 
by endogenous E3-ubiquitin ligases. These results indicate clear 
competition between sumoylation and ubiquitination for posttrans-
lational modification of AMPKβ2 subunit.
Ubiquitination of AMPKβ2 occurs at the C-terminus of the pro-
tein (Qi et al., 2008). Because we constructed an AMPKβ2 mutant 
in this area (K262R; Figure 5), we examined whether this mutant 
could be properly ubiquitinated by endogenous E3-ubiquitin li-
gases. With this aim, we coexpressed in HEK293 cells the three 
AMPK subunits (α2/β2/γ1) containing either wild-type AMPKβ2 or 
the K262R mutant, together with 6xHis-ubiquitin. Cells were then 
treated with MG132 to inhibit proteasome activity, and then cell 
compartment and then is exported to the cytosol, where accumu-
lates in the form of cytoplasmic deposits. Consistent with this 
hypothesis, treatment of cells with leptomycin B, an inhibitor of the 
CRM1-dependent nuclear protein export pathway, resulted in the 
appearance of AMPKβ2-containing granules inside the nucleus 
(Supplemental Figure S2B).
We quantified the cells containing AMPKβ2 deposits and 
observed that when PIASy and SUMO2 were coexpressed with the 
three AMPK subunits, 60% of the cells contained these inclusions 
(Figure 7C). The appearance of these deposits was dependent on 
the presence of PIASy, since only 30% of cells presented these inclu-
sions if only SUMO2 was coexpressed with the trimeric AMPK 
complex (Figure 7C). Similar basal levels of these deposits (30%; 
Figure 7C) were observed in cells transfected with PIASy and 
SUMO1, indicating that the increase in the appearance of the inclu-
sions was due to an efficient SUMO2-dependent sumoylation of 
AMPKβ2 (as indicated earlier, PIASy does not carry out an efficient 
sumoylation of AMPKβ2 using SUMO1; Figure 2A). The observed 
inclusion bodies contained SUMO2, as they were stained with anti-
SUMO2 antibodies (Figure 7B). All of these results confirmed that 
PIASy promotes the SUMO2-dependent sumoylation of AMPKβ2, 
resulting in the formation of cytoplasmic protein deposits.
Finally, we analyzed the effect of PIASy-dependent sumoylation 
of AMPKβ2 on the activity of the AMPK complex. AMPK activity was 
assessed by its ability to phosphorylate acetyl-CoA carboxylase 
(ACC), one of its specific substrates, and also by the phosphoryla-
tion status of AMPKα2 catalytic subunit at Thr-172, a sign of activa-
tion. In this assay we used the hypersumoylable AMPKβ2 K262R 
FIGURE 6: Degradation rates of AMPKβ2 in the presence of PIASy 
and SUMO2. HEK293 cells were cotransfected with plasmids 
pCMV-myc-AMPKα2/β2/γ1, pCMV-6xHis-SUMO2, and pFLAG-PIASy 
or pFLAG (empty). Twenty-four hours after transfection, 
cycloheximide (CHX; 100 μM) was added to the cultures, and cell 
extracts were analyzed by Western blotting at the indicated times, 
using anti-AMPKβ (top) and anti-actin (bottom) antibodies. The 
relative intensity of the AMPKβ2 bands with respect to the 
corresponding actin band is plotted as a function of time. Diagram 
shows means of three independent experiments; bars, SD.
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Because ubiquitination of AMPKβ2 medi-
ated by CIDEA results in rapid degradation 
of the protein, we examined whether the 
reduced capacity of the AMPKβ2 K262R 
mutant to be ubiquitinated could prevent 
CIDEA-mediated degradation. We coex-
pressed in HEK293 cells the three AMPK 
subunits (α2/β2/γ1) containing either wild-
type AMPKβ2 or the K262R mutant in the 
presence or absence of FLAG-CIDEA. In 
agreement with previous results, CIDEA in-
duced the degradation of wild-type AMPKβ2 
(Qi et al., 2008). However, CIDEA-induced 
degradation of AMPKβ2 K262R was pre-
vented to some degree (Figure 9D). Taking 
all these results together, we suggest that 
K262 is a residue important for the ubiquit-
ination of AMPKβ2. If ubiquitination at this 
site is prevented (K262R mutant), then the 
protein becomes a poorer substrate for 
ubiquitination, which prevents its protea-
somal degradation. At the same time, the 
protein becomes more competent to be 
posttranslationally modified by sumoylation 
(hypersumoylable mutant).
DISCUSSION
We report here that PIASy, an E3-SUMO li-
gase, interacts physically with and promotes 
the sumoylation of AMPKβ2 subunit when it 
forms part of a heterotrimeric AMPK com-
plex. We studied this modification in more 
detail and observed that PIASy is able to 
promote the attachment of only SUMO2 
conjugates but not SUMO1. This observa-
tion is in agreement with other examples of 
sumoylated proteins that become modified 
only by one of the SUMO conjugates and 
not by the other (Saitoh and Hinchey, 2000). 
However, sumoylation of free AMPKβ2 sub-
units becomes independent of PIASy, indi-
cating that the E2-SUMO–conjugating en-
zyme Ubc9 is able to sumoylate the free 
subunit but requires the help of the E3-
SUMO ligase PIASy to gain access to the 
corresponding Lys residues when AMPKβ2 
is in the heterotrimeric AMPK complex.
Although PIASy interacted physically 
with AMPKβ1 subunit, surprisingly, PIASy 
was not able to modify this subunit in spite 
of the high similarity between both AMPKβ 
subunits. Perhaps AMPKβ1 lacks specific Lys 
residues present in AMPKβ2. In fact, align-
ment of the sequence of both subunits high-
lights the presence of five residues that are present in AMPKβ2 but 
not in AMPKβ1. We tried to identify the Lys residues involved in the 
sumoylation reaction, first, by applying a bioinformatics approach to 
identify putative sumoylation consensus sites, and second, by map-
ping the region of the AMPKβ2 subunit that is subjected to this 
modification. However, mutation of the suggested Lys residues (K71 
and K167 by the bioinformatics approach, and K203 by the map-
ping strategy) did not prevent the PIASy-dependent sumoylation of 
extracts were purified by metal-affinity chromatography. As shown 
in Figure 9C, we observed a clear ubiquitination of wild-type 
AMPKβ2. However, in the case of AMPKβ2 K262R, the ubiquitina-
tion process was much less efficient. These results suggested that 
residue K262 affected the ubiquitination of AMPKβ2, either because 
it was a ubiquitination site (so the K262R mutant would lack this site) 
or because the K262R mutant promoted a conformational change 
that affected the ubiquitination of Lys residues in the vicinity. 
FIGURE 7: PIASy-dependent sumoylation of AMPKβ2 promotes its aggregation. (A) HEK293 
cells were cotransfected with plasmids expressing the AMPK subunits (pCMV-myc-
AMPKα2/β2/γ1), pCMV-6xHis-SUMO2, and pFLAG-PIASy or pFLAG empty vector. The 
subcellular localization of AMPKβ2 subunit was carried out as described in Materials and 
Methods by using anti-AMPKβ as a primary and anti-rabbit Alexa Fluor 488 as a secondary 
antibody. The same samples were also immunodetected with anti-FLAG as a primary and 
anti-mouse Texas red as a secondary antibody to determine the localization of PIASy. All the 
samples were treated with Topro3 to stain the nucleus, and the three images were subjected to 
a merge analysis. (B) Similar samples were used to immunodetect AMPKβ2 subunit using 
anti-myc as a primary and anti-mouse Texas red as a secondary antibody and also to 
immunodetect SUMO-modified proteins using anti-SUMO2 as a primary and Alexa Fluor 488 as 
a secondary antibody. (C) Quantification of cells expressing AMPKβ2 and showing a granular 
pattern of intracellular inclusions. One hundred cells expressing AMPKβ2 from each of the 
indicated conditions were used to estimate the proportion of cells with intracellular inclusions. 
Values are mean ± SD; statistical significance was considered at *p < 0.05, **p < 0.01, and 
***p < 0.001.
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dation rate. However, we observed that HEK293 cells coexpressing 
PIASy, SUMO2, and AMPK subunits produced cytoplasmic deposits 
that were positive for AMPKβ2 and SUMO2. The fact that the over-
expression of PIASy and SUMO1 did not produce these aggregates 
indicates that sumoylation of AMPKβ2 with SUMO2 triggered the 
appearance of these deposits. These results suggest that sumoyla-
tion produces two pools of AMPKβ2 that might coexist in the cells: 
the mutated forms. Thus either other Lys residues are involved in 
this modification or the absence of one particular Lys residue en-
ables other Lys residues in the vicinity to become competent in the 
sumoylation reaction.
We also studied the effect of PIASy-dependent sumoylation on 
AMPK stability and function. Consistent with the idea that poly-
SUMO modification does not usually trigger protein degradation 
(Gareau and Lima, 2010; Wilkinson and Henley, 2010), we show that 
PIASy-dependent sumoylation of AMPKβ2 does not affect its degra-
FIGURE 8: PIASy-dependent sumoylation of AMPKβ2 enhances the 
activity of the AMPK complex. (A) HEK293 cells were cotransfected 
with pCMV-myc-AMPKα2/γ1 and pCMV-myc-AMPKβ2 or pCMV-myc-
AMPKβ2 K262R and pCMV-6xHis-SUMO2 and pFLAG-PIASy or 
pFLAG (empty). Twenty-four hours after transfection, cells were 
treated with 5 mM phenformin for different times. Cells extracts were 
analyzed by Western blotting using anti–pThr-172AMPKα, anti-
AMPKα, anti–pSer-79ACC, and anti-pACC antibodies. The relative 
intensity of the phosphorylated bands with respect to the amount of 
the corresponding total protein was plotted as a function of time 
(time 0 and after 60 min of the treatment). Values are means from 
three independent assays (bars, ±SD). Statistical significance was 
considered at *p < 0.05. (B) Cells expressing a combination of 
plasmids pCMV-HA-AMPKα2, pCMV-myc-AMPKβ2 (WT or K262R), 
and pCMV-HA-AMPKγ1 were cotransfected or not with plasmids 
pFLAG-PIASy and pCDNA3–6His-SUMO2. Cell extracts were 
immunoprecipitated using anti-myc antibody to pull-down the AMPK 
complex and the in vitro kinase activity measured in the 
immunoprecipitates as indicated in Materials and Methods. Values 
indicate the 32P incorporation into GST-ACC relative to the levels of 
catalytic AMPKα2 in the immunoprecipitates. Statistical significance 
was considered at *p < 0.05.
FIGURE 9: Sumoylation and ubiquitination of AMPKβ2 are 
antagonistic processes. (A) The coexpression of HA-ubiquitin 
decreases the levels of PIASy-dependent sumoylated AMPKβ2 
protein. HEK293 cells were cotransfected with plasmids pCMV-6xHis-
SUMO2, pCMV-myc-AMPKα2/β2/γ1, pFLAG-PIASy, and pCMV-HA-
ubiquitin or pCMV-HA (empty) vector. Cell extracts were analyzed as 
described in Figure 2 by using anti-AMPKβ antibody. (B) The 
coexpression of HA-SUMO2 decreases the levels of ubiquitinated 
AMPKβ2 protein. HEK293 cells were cotransfected with plasmids 
pCMV-6xHis-ubiquitin and pCMV-myc-AMPKα2/β2/γ1, in the 
presence or absence of pFLAG-PIASy and pCMV-HA-SUMO2. 
Twenty-four hours after transfection, cells were treated with 6 μM 
MG132 during 8 h. Then cell extracts were analyzed as described in 
Figure 2 by using anti-AMPKβ antibodies. (C) Ubiquitination of 
AMPKβ2 K262R is less efficient than for wild-type protein. HEK293 
cells were cotransfected with plasmids pCMV-6xHis-ubiquitin, 
pCMV-myc-AMPKα2/γ1, and pCMV-myc-AMPKβ2 or pCMV-myc-
AMPKβ2K262R mutant. Cells were treated with 6 μM MG132 during 
8 h, and cells extracts were analyzed as described in Figure 2 by using 
anti-AMPKβ antibody. (D) CIDEA-dependent degradation of AMPKβ2 
is prevented to some degree in AMPKβ2 K262R mutant. HEK293 cells 
were cotransfected with pCMV-myc-AMPKα2/γ1 and pCMV-myc-
AMPKβ2 or pCMV-myc-AMPKβ2 K262R mutant and FLAG-CIDEA or 
pFLAG empty vector. Twenty-four hours after transfection, cell 
extracts (40 μg) were analyzed by SDS–PAGE and immunodetected 
with anti-AMPKβ and anti-tubulin antibodies.
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GCTGCTGG-3′), and pCDNA3–6His-SUMO2 as template. The PCR 
product was digested with EcoRI/SfiI and subcloned into the pCMV-
HA vector. pCMV-myc plasmids containing AMPKβ2 mutants were 
obtained by site-directed mutagenesis using the corresponding 
pairs of primers: K71Rfor (5′-CAGGATTTGGAGGACTCCGTAAG-
GCCCACACAGCAGGCCCGGCCC-3′) and K71Rrev (5´-GGGCCG-
GGCCTGCTGTGTGGGCCTTACGGAGTCCTCCAAATCCTG-3′); 
K167Rfor (5´-TTTGAGGTGTTCGATGCTTTAAGGTTAGATTCTATG-




CTTTCCTCAGATCGAAA-3′); and K262Rfor (5´-GCAACCCATCGC-
TACAAGAAGAGGTATGTTACTACTCTGCTATAC-3´) and K262Rrev 
(5´-GTATAGCAGAGTAGTAACATACCTCTTCTTGTAGCGATGGGT-
TGC-3′). Mutations and construct fidelity were confirmed by DNA 
sequencing. Other plasmids used in this study were pBTM-AMPKα2, 
pBTM-AMPKβ2, and pBTM-AMPKγ1 (Gimeno-Alcaniz and Sanz, 
2003) and pCMV-myc-AMPKα2, pCMV-myc-AMPKβ2, pCMV-myc-
AMPKγ1, pCMV-HA-AMPKα2, and pCMV-HA-AMPKγ1 (Solaz-Fuster 
et al., 2008). Plasmid pCMV-myc-β2-1, containing the N-terminal 
fragment of AMPKβ2 (residues 1–185), plasmid pCMV-myc-β2-2, 
containing the C-terminal part of AMPKβ2 (residues 186–271), and 
plasmids pFLAG-CIDEA, pCMV-HA-ubiquitin, and pCMV-6xHis-
ubiquitin were previously described (Moreno et al., 2010).
Cell culture and immunoblotting analysis
Human embryonic kidney (HEK293) and human osteosarcoma 
U2OS cells were grown in DMEM (Lonza, Barcelona, Spain) supple-
mented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM 
glutamine, and 10% inactivated fetal bovine serum (Invitrogen, 
Madrid, Spain). We plated 1.5 × 106 or 3 × 106 cells onto 60-mm-
diameter (p60) or 100-mm-diameter (p100) culture dishes, respec-
tively, the day before transfection. Cells were transfected with 
1 μg (for p60 culture dishes) or 3 μg (for p100 culture dishes) of 
each plasmid using Lipofectamine 2000 (Invitrogen). Twenty-four 
hours after transfection, cells were treated when indicated with 
5 mM phenformin (Sigma-Aldrich, Madrid, Spain), 6 μM MG132 
(Enzo-Biomol, Madrid, Spain), or 100 μM cycloheximide (Sigma-
Aldrich). Then cells were scraped on ice in lysis buffer (10 mM 
Tris-HCl, pH 7.0, 15 mM EDTA, pH 8.0, 50 mM NaF, 0.6 M sucrose, 
5 mM Na2P2O7, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 1 μM microcystine, 1 mM NaVO4, 
and protease inhibitor mixture [Roche, Barcelona, Spain]). Forty 
micrograms of total protein from the soluble fraction of cell lysates 
was analyzed by SDS–PAGE and Western blotting using appropriate 
antibodies: anti-AMPKα total, anti-AMPKβ total, anti-ACC total, 
anti–pSer-79 ACC, and anti–pThr-172 AMPKα (Cell Signaling, 
Barcelona, Spain); anti-PIASy and anti-SUMO2/3 (Abcam, Cambridge, 
United Kingdom); and anti-myc and anti-actin (Sigma-Aldrich).
Yeast two-hybrid analyses
The yeast strain CTY10.5d was cotransformed with combinations of 
pACT2-PIASy and different pBTM-AMPKα2, pBTM-AMPKβ2, and 
pBTM-AMPKγ1 plasmids. Transformants were grown in selective 
synthetic complete medium, and β-galactosidase activity was as-
sayed in permeabilized cells and expressed in Miller units (Ludin 
et al., 1998).
Coimmunoprecipitation analyses
HEK293 cells transfected with plasmid pFLAG-PIASy or empty 
vector and a combination of plasmids pCMV-myc-AMPKα2, 
one pool forms part of these inclusions bodies, with unknown func-
tion, and another pool is soluble and responsible for AMPK activity.
We also found that PIASy-dependent sumoylation of AMPKβ2 
enhances the activity of the AMPK complex. Both the phosphoryla-
tion status of Thr-172 (a sign of AMPK activation) and the phospho-
rylation of ACC (a typical AMPK substrate) were enhanced in cells 
containing sumoylated forms of AMPKβ2. This is a very important 
result since it indicates that sumoylation of AMPK is another post-
translational modification that renders an active AMPK complex. 
Therefore conditions that enhance PIASy activity could result in the 
activation of the AMPK complex. We do not know the molecular 
mechanism by which sumoylation of AMPKβ2 enhances AMPK ac-
tivity. Perhaps this posttranslational modification provides a novel 
change in the conformation of the AMPK complex that either in-
creases the action of upstream kinases or makes it a poorer sub-
strate for specific phosphatases.
Because sumoylation and ubiquitination are very similar pro-
cesses, both based on the modification of Lys residues, it is likely that 
in some cases both processes may compete for the same Lys site. In 
this work we present evidence for a competition between sumoyla-
tion and ubiquitination in the posttranslational modification of 
AMPKβ2. Our results indicate that sumoylation of AMPKβ2 subunit is 
decreased if ubiquitin is overexpressed and also that ubiquitination of 
AMPKβ2 is reduced if sumoylation is enhanced. Perhaps sumoylation 
of AMPKβ2 could provide a conformational change in the protein 
resulting in a protein structure less competent to be ubiquitinated, or, 
conversely, sumoylation and ubiquitination may compete for the 
same target site in AMPKβ2 sequence. Because the final effect of 
these two posttranslational modifications is different (ubiquitination 
triggers inactivation of AMPK; sumoylation enhances AMPK activity), 
we propose that these two processes are competitors and have an-
tagonist effects in AMPK complex activity. This adds an extra layer of 
complexity to the regulation of the activity of AMPK complex, since 
conditions that promote one or the other type of these posttransla-
tional modifications may result in different outcomes.
In summary, our results indicate that the AMPKβ2 subunit can be 
sumoylated in a process dependent on PIASy and SUMO2 and that 
this modification results in an enhancement of AMPK activity. Of in-
terest, this modification does not occur in the AMPKβ1 subunit, 
which opens a new way to activate selectively AMPKβ2-containing 
complexes. In addition, our results indicate that sumoylation and 
ubiquitination of AMPKβ2 are antagonistic processes.
MATERIALS AND METHODS
Plasmids
Plasmid pACT2-PIASy was a generous gift from Santiago Rodriguez 
de Cordoba (Centro de Investigaciones Biológicas, Consejo Supe-
rior de Investigaciones Científicas, Madrid, Spain). Plasmids pCMV-
myc-PIASy and pFLAG-PIASy were obtained by subcloning an 
EcoRI/SalI fragment from pACT2-PIASy into pCMV-myc and pFLAG 
vectors. Plasmids pCDNA3–6xHis-SUMO1 and pCDNA3–6xHis-
SUMO2 were from R. T. Hay (College of Life Science, University of 
Dundee, Scotland). Plasmid pCDNA3-myc-PIASy CI (C342/347A; 
expressing a form with reduced catalytic activity) was from Shigeki 
Miyamoto (Division of Food Science and Biotechnology, Graduate 
School of Agriculture, Kyoto University, Kyoto, Japan); this plasmid 
was digested with EcoRI/XbaI and the resulting fragment subcloned 
into pFLAG vector to obtain the pFLAG-PIASy CI plasmid. Plasmid 
pCMV-HA-SUMO2 was constructed by amplifying by PCR a frag-
ment containing the SUMO2 open reading frame, using primers 
SUMO2-for (5′-CATCAGGCCATGGAGGCCATGTCCGAGGAGAA-
GCCC-3′), SUMO2-rev (5′-TCTGCAGAATTCCTAACCTCCCGTCT-
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times with buffer C adjusted to pH 8.0 (buffer B but with 8 M urea 
instead of 6 M guanidinium-HCl). Bound proteins were eluted with 
30 μl of 2× Laemmli sample buffer and analyzed by Western blotting 
using appropriated antibodies.
Analysis of the degradation rates of AMPKβ2 subunit
HEK293 cells were transfected with plasmids pCMV-myc-AMPKβ2, 
pCMV-myc-AMPKα2, pCMV-myc-AMPKγ1, pCDNA3–6xHis-SUMO2, 
and pFLAG-PIASy or pFLAG empty vector. Twenty-four hours after 
transfection, cells were treated with 100 μM cycloheximide and, at 
the indicated times (from 0 to 8 h), aliquots were taken from the 
cultures, and cell extracts (40 μg) were analyzed by SDS–PAGE and 
Western blotting using anti-AMPKβ antibody. The same extracts 
were analyzed using anti-actin antibody as a loading control. 
Western blots were analyzed by densitometry using an LAS-3000 
electronic reader and Image Gauge, version 4.0, software (Fujifilm, 
Tokyo, Japan). The levels of the corresponding AMPKβ2 subunit 
with respect to those of actin at each time point are expressed as a 
percentage of values at time zero.
Immunofluorescence and confocal microscopy
HEK293 cells transfected with the appropriate plasmids were grown 
on plates containing coverslips. Cells were fixed with 4% paraform-
aldehyde in phosphate-buffered saline (PBS) for 10 min, and then 
the fixation was stopped with 10 mM glycine for 5 min. Cells were 
permeabilized with 0.5% Triton X-100 in PBS for 30 min. Samples 
were washed three times with PBS and blocked with 10% fetal bo-
vine serum, 5% nonfat dried milk, and 0.1% Triton X-100 in PBS for 
1 h at room temperature. Samples were then incubated overnight 
at 4°C with a 1:200 dilution of anti-AMPKβ total (Cell Signaling 
Technology) with or without anti-FLAG (1:200) in blocking solution. 
Samples were washed five times with PBS during 1 h at room tem-
perature and incubated again with 1:500 dilution of appropriated 
fluorescence-labeled secondary antibodies (anti-rabbit Alexa Fluor 
488 and anti-mouse Texas red; Invitrogen). Nuclei were stained with 
1:1000 dilution of a Topro3 fluorescent probe in PBS for 30 min. 
Finally, samples were washed again with PBS and mounted on slices 
using Fluoromount G. Images were acquired for 20-μm slices with a 
TCS/SP2 confocal microscope (Leica, Wetzlar, Germany) using a 63× 
oil immersion objective. Images were treated with ImageJ 1.43c 
software (National Institutes of Health, Bethesda, MD). More than 
100 green cells (therefore containing AMPKβ) were analyzed for 
each condition and used to determine the presence or absence or 
large intracellular inclusions. Because in cotransfection experiments 
some of the green cells may not contain the rest of the plasmids, the 
quantification of cells containing large inclusions could be underes-
timated. When indicated, cells were treated with 20 ng/ml leptomy-
cin B (Sigma-Aldrich) for 20 min.
Statistical analyses
Values are given as mean ± SD of at least three independent experi-
ments. Differences between groups were analyzed by two-tailed 
Student’s t tests. The significance is considered at *p < 0.05 and 
**p < 0.01, as indicated in each case.
pCMV-myc-AMPKβ2, and pCMV-myc-AMPKγ1 were used for coim-
munoprecipitation studies. Transfected cells were scraped in ice-
cold lysis buffer (10 mM NaCl, 10 mM Tris-HCl, pH 7, 0.5% Nonidet 
P-40, 5 mM NaF, 5 mM Na2P2O7, 1 mM PMSF, 1 mM NaVO4, and 
protease inhibitor mixture [Roche]) and then clarified by centrifuga-
tion at 5000 × g for 5 min at 4 °C. Then 1.2 mg of total protein from 
the soluble fraction was used for immunoprecipitation using specific 
anti-FLAG antibody (Sigma-Aldrich) and protein A/G-plus agarose 
(Santa Cruz Biotechnology, Barcelona, Spain). Immunoprecipitates 
were analyzed by Western blotting using polyclonal specific anti-
bodies: anti-AMPKα, anti-AMPKβ, anti-AMPKγ (Cell Signaling Tech-
nology), and anti-PIASy (Abcam). HEK293 cells were also transfected 
with plasmid pFLAG-PIASy and a combination of plasmids pCMV-
HA-AMPKα2, pCMV-myc-AMPKβ2, and pCMV-HA-AMPKγ1 and 
used in immunoprecipitation studies using anti-myc antibody. The 
resulting immunoprecipitates were analyzed by Western blotting 
using anti-AMPKα, anti-AMPKβ, anti-AMPKγ (Cell Signaling), and 
anti-PIASy (Abcam) antibodies.
Human osteosarcoma U2OS cells were treated with 6 μM MG132 
(8 h). Then cell extracts were immunoprecipitated using anti-PIASy 
(Abcam) antibodies and the immunoprecipitates analyzed by 
Western blot using anti-AMPKα, anti-AMPKβ, and anti-AMPKγ (Cell 
Signaling) antibodies.
Analysis of in vitro kinase activity
Cells expressing a combination of plasmids pCMV-HA-AMPKα2, 
pCMV-myc-AMPKβ2 (wild type or K262R), and pCMV-HA-AMPKγ1 
were cotransfected or not with plasmids pFLAG-PIASy and pCDNA3–
6His-SUMO2. Cell extracts were immunoprecipitated using anti-myc 
antibody to pull-down the AMPK complex. Immunoprecipitates 
were divided into two aliquots: one-third was used to determine the 
amount of the catalytic AMPKα2 subunit present in the pellet by 
Western blotting using anti-AMPKα antibody, and two-thirds of the 
immunoprecipitates were used to carry out in vitro kinase activity in 
the following way: immunoprecipitates were resuspended in 20 μl of 
kinase buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM dithio-
threitol) containing 0.5 μg glutathione S-transferase (GST)–ACC1 
(a generous gift of Mhairi Towler, University of Dundee, Dundee, 
Scotland). After the addition of 2 μl of [γ-32P]ATP (3000 Ci/mmol) to 
the samples, reactions were incubated at 30ºC for 30 min and 
stopped by boiling the mixtures in sample buffer. Samples were ana-
lyzed by SDS–PAGE and autoradiography, and gels were subjected 
to phosphoimaging for the measurement of 32P incorporation. This 
value was related to the levels of AMPKα2 in the immunoprecipi-
tates and adjusted to the value of wild-type AMPK complex.
Analysis of in vivo sumoylation
To study sumoylation in intact cells, HEK293 cells were transfected 
with plasmid pCDNA3–6xHis-SUMO1 or pCDNA3–6xHis-SUMO2 
(encoding modified forms of SUMO1 and SUMO2, respectively, 
tagged with six His residues), pCMV-myc plasmids encoding the 
AMPK subunits (α2, β1/2, and γ1), and pFLAG-PIASy wild type (WT) 
or pFLAG-PIASy CI (expressing a form with reduced activity) plas-
mids, by using the Lipofectamine 2000 reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. After 24 h of transfection, cells 
were lysed in buffer A (6 M guanidinium-HCl, 0.1 M sodium phos-
phate, 0.1 M Tris-HCl, pH 8.0). We incubated 1.5 mg of protein of a 
clarified extract (CE; 12,000 × g for 15 min) in 150 μl of TALON col-
umn (Clontech, Madrid, Spain) in the presence of 10 mM imidazole 
for 2 h at room temperature on a rocking platform to purify His-
tagged proteins. The column was then successively washed with 
1 ml each of buffer B (buffer A plus 10 mM imidazole) and four more 
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